- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03143374
PET Tau - Neurodegenerative Disease Imaging
Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease
Study Overview
Detailed Description
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells, including Alzheimer's disease, Parkinson's disease, Lewy body disease and Frontotemporal degeneration. 18F-AV-1451 (formally known as 18F-T807) is a specialized radioactive PET tracer that sticks to the tau protein in the brain. In this study, researchers will use 18F-AV-1451 to form images of tau binding in the brain. 18F-AV-1451 is an investigational or experimental imaging agent that has not yet been approved by the Food and Drug Administration for use in brain imaging.
In this study, researchers want to find out how accurate and useful 18F-AV-1451 is in imaging patients who have problems with thinking, remembering, speech, and visual activities, and may be diagnosed with different types of neurodegenerative disease. This study will help test how imaging measures may provide information that could be used to determine diagnosis for patients in the future. The results of the PET/CT scan will be compared with other information obtained under related protocols, including brain magnetic resonance imaging (MRI), spinal fluid and cognitive test results.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Dahlia Kamel
- Phone Number: 215-662-6134
- Email: kamel.dahlia@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Dahlia Kamel
- Phone Number: 215-662-6134
- Email: kamel.dahlia@pennmedicine.upenn.edu
-
Principal Investigator:
- David Irwin, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS
- Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
- Participants will be 18 years of age or older
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol.
INCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
- Participants will be 18 years of age or older.
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol
EXCLUSION CRITERIA FOR ALL SUBJECTS
- Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
- Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
- Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
- The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
- The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
ADDITIONAL EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
- Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report.
- Current use of psychoactive medications or substances per medical record review or self-report.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease
Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology.
Healthy control subjects will also be recruited for this study.
|
The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit. The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regional uptake
Time Frame: 10 years
|
Examine regional anatomic distribution of PET-tau uptake comparatively in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline collected under other center protocols.
Uptake with neuropsychology and MRI regional GM atrophy at baseline.
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes over time
Time Frame: 10 years
|
Use regression to relate longitudinal neuropsychological and regional MRI decline in dementia syndromes to baseline regional PET-tau uptake.
|
10 years
|
CSF Correlate
Time Frame: 10 years
|
Correlate CSF total and phosphorylated (p-tau/t-tau) tau with regional PET-tau uptake in dementia syndromes at baseline.
|
10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Irwin, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 824867
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodegenerative Disease
-
Fujian Medical University Union HospitalRecruitingNeurodegenerative DisorderChina
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseUnited States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseSerbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
-
National Institute of Neurological Disorders and...Completed
-
Xuanwu Hospital, BeijingCompletedNeuro-Degenerative Disease
-
University Health Network, TorontoRecruiting
-
IRCCS San RaffaeleCompleted
-
Chinese University of Hong KongEnrolling by invitationNeuro-Degenerative DiseaseHong Kong
-
University Hospital, BordeauxUnknown
-
University Health Network, TorontoRecruiting
Clinical Trials on 18F-AV-1451
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Northwestern UniversityNational Institute on Aging (NIA)RecruitingPrimary Progressive Aphasia With Suspected Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaAvid Radiopharmaceuticals; Alzheimer's Therapeutic Research Institute; Alzheimer...CompletedCognition DisordersUnited States
-
Tammie L. S. Benzinger, MD, PhDCompletedAlzheimer DiseaseUnited States
-
University of PennsylvaniaNational Institutes of Health (NIH); National Institute on Aging (NIA)Recruiting
-
University of ZurichAvid Radiopharmaceuticals; Swiss Federal Institute of TechnologyActive, not recruitingHealthy | Neurocognitive Disorders | Alzheimer Disease | Mild Cognitive ImpairmentSwitzerland
-
Tammie L. S. Benzinger, MD, PhDCompletedAlzheimer Disease | HIVUnited States
-
Tammie L. S. Benzinger, MD, PhDRecruiting
-
Washington University School of MedicineEnrolling by invitationAlzheimer DiseaseUnited States
-
Tammie L. S. Benzinger, MD, PhDCompletedAlzheimer Disease | Progressive Posterior Cortical Dysfunction (PPCD)United States